US equities |
MU $982.80 ▲+5.82% META $614.19 ▼-0.97% NVDA $216.66 ▼-0.59% TSLA $403.87 ▼-0.88% SPCX $145.15 ▼-2.31% SNDK $1,401.21 ▲+7.39% GOOGL $326.04 ▲+1.70% ORCL $146.81 ▲+12.48%
FinancialContent

NRX Pharmaceuticals, Inc. - Common Stock (NQ:NRXP)

2.660 -0.030 (-1.12%)
Delayed Quote Updated: 3:03 PM EDT, Oct 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NRX Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
News headline image
Final Step Completed for FDA Process Validation; Two-Year Stability for Preservative-Free Ketamine Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
$11 Million Dollar Award for Robotic Magnetic Stimulation with Pharma Treatment for Resistant Depression Greatly Expands Application Potential for NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
Topics Intellectual Property
News headline image
NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
First Interventional Psychiatry Use of FDA-Cleared Zeta TMS AI Driven Robotic System in Treatment of Suicidal Bipolar Depression by NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
Topics Artificial Intelligence
News headline image
GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals to Participate in Upcoming Investor Conferences
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
FDA First Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies Noted for Suicidal Bipolar Depression Treatment from NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
News headline image
NRX Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript ↗
NRX Pharmaceuticals (NASDAQ:NRXP) released second-quarter financial results and hosted an earnings call on Monday. Read the complete transcript below. This content is powered by Benzinga APIs. For... 
Via Benzinga
Topics Earnings
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles ↗
NRx Pharmaceuticals (NASDAQ:NRXP) said it has completed the first-cycle U.S. Food and Drug Administration review of its abbreviated new drug application, or ANDA, for preservative-free ketamine, with... 
Via MarketBeat
News headline image
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans
Conference Call 8:30 a.m. ET, Monday, August 10, 2026 
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
First Patients Treated via FDA-Cleared Transcranial Magnetic Stimulation, Plus FDA Grant on D-Cycloserine-Based Drug for Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
Topics Government
News headline image
New to The Street Announces Broadcast of Show #759 on Bloomberg Television Across the U.S., MENA and Latin America tonight 630pm est.
From New to The Street
Via ACCESS Newswire
News headline image
NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA
From New to The Street
Via ACCESS Newswire
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option
Offering was led by B Group Capital with significant participation from, among others, Columbia Threadneedle Investments, Corbets Capital, Venture 76, and Mossrock Capital 
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
These stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
What's going on in today's after hours session ↗
Via Chartmill
News headline image
NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
First Commercial Deployment of FDA-Cleared Transcranial Magnetic Stimulation (TMS) for Major Depressive Disorder and Other Neurological Conditions: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
Topics Government
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >